Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 32%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is a solid long-term investment as they have a strong presence in the insulin pump market, are shifting towards the pharmacy channel for more sustained revenue, and have a new product launch planned for the second half of the year. With plans to achieve significant market share and impressive growth and profitability targets, TNDM's focus on automated insulin delivery and transition to a Pay/Go model have the potential for long-term success, despite potential risks.

Bears say

Tandem Diabetes Care is a company with a narrow focus on designing and selling insulin pumps mainly in the US, accounting for the majority of its revenue. However, the pumps only account for half of its total sales and the company's profitability has been impacted by headwinds in new patient growth. Despite growth potential from new products and a potential pharmacy strategy, a negative financial outlook remains due to uncertainties around market positioning and potential upside in revenue and profitability from these efforts.

TNDM has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 32% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 19 analysts, TNDM has a Buy consensus rating as of Jul 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.